Comparison of H2-receptor antagonist- and proton-pump inhibitor-based triple regimens for the eradication of Helicobacter pylori in Chinese patients with gastritis or peptic ulcer.

Abstract

This study compared the efficacy of an H2-receptor antagonist (H2RA)- and a proton-pump inhibitor (PPI)-based triple regimen for the eradication of Helicobacter pylori infection. Chinese patients with H. pylori-associated gastritis or peptic ulcer were randomized to receive the H2RA-based triple regimen (20 mg famotidine, 1.0 g amoxicillin and 0.4 g metronidazole) or the PPI-based triple regimen (20 mg omeprazole, 1.0 g amoxicillin and 0.4 g metronidazole) both twice daily for 1 or 2 weeks. Successful eradication of H. pylori was determined by the 13C-urea breath test and gastric mucosa histology at least 4 weeks after completion of antibiotic therapy. Eradication rates were 56.0% and 76.9% for the 1-week H2RA- and PPI-based triple regimens, respectively, and 81.6% and 82.1% for the 2-week regimens, respectively. The H. pylori eradication rate for the 2-week H2RA regimen was significantly higher than that for the 1-week regimen, but there were no significant differences between the 1- and 2-week PPI regimens. The two regimens proved equally effective in eradicating H. pylori infection.

• Authors: F L Hu, J C Jia, Y L Li, G B Yang
• Journal: The Journal of international medical research (J Int Med Res) 2003 Nov-Dec Vol. 31 Issue 6 Pg. 469-74 ISSN: 0300-0605 [Print] England
• PMID: 14708410 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)

Chemical References

• Anti-Ulcer Agents
• Enzyme Inhibitors
• Histamine H2 Antagonists
• Proton Pump Inhibitors
• Metronidazole
• Famotidine
• Amoxicillin
• Omeprazole

Topics

• Adolescent
• Adult
• Aged
• Amoxicillin (therapeutic use)
• Anti-Ulcer Agents (adverse effects, therapeutic use)
• China
• Drug Therapy, Combination
• Enzyme Inhibitors (adverse effects, pharmacology)
• Famotidine (therapeutic use)
• Female
• Gastritis (drug therapy, microbiology)
• Helicobacter Infections (drug therapy, microbiology)
• Helicobacter pylori (pathogenicity)
• Histamine H2 Antagonists (adverse effects, therapeutic use)
• Humans
• Male
• Metronidazole (therapeutic use)
• Middle Aged
• Omeprazole (therapeutic use)
• Pain (drug therapy)
• Peptic Ulcer (drug therapy, microbiology)
• Proton Pump Inhibitors
• Treatment Outcome